Advanced search
Publication Cover
ClinicoEconomics and Outcomes Research Volume 7, 2015 - Issue
Submit an article Journal homepage
95
Views
8
CrossRef citations to date
0
Altmetric
Original Research

Estimating the real world daily usage and cost for exenatide twice daily and liraglutide in Germany, the Netherlands, and the UK based on volumes dispensed by pharmacies

Amanda L McDonell1 IMS Health, London, UKCorrespondence[email protected]
,
Urpo Kiiskinen2 Eli Lilly and Company, Helsinki, Finland
,
Danielle C Zammit3 IMS Health, Basel, Switzerland
,
Robert W Kotchie1 IMS Health, London, UK
,
Per-Olof Thuresson3 IMS Health, Basel, Switzerland
,
Claudia Nicolay4 Eli Lilly and Company, Bad Homburg, Germany
,
Thomas Haslam1 IMS Health, London, UK
,
Michiel Bruinsma5 IMS Health, Rotterdam, the Netherlands
,
Anne-Jeanine Janszen-Van Oosterhout6 Eli Lilly Nederland, Houten, the Netherlands
&
Thorsten Otto4 Eli Lilly and Company, Bad Homburg, Germany
 show all
Pages 95-103 | Published online: 30 Jan 2015

Citations (8)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Thorsten Otto, Melissa Myland, Heike Jung, Jeremie Lebrec, Hartmut Richter & Kirsi Norrbacka. (2019) Utilization patterns of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus in Germany: a retrospective cohort study. Current Medical Research and Opinion 35:5, pages 893-901.
Read now

Articles from other publishers (7)

Constance Stegbauer, Camilla Falivena, Ariadna Moreno, Anna Hentschel, Magda Rosenmöller, Tim Heise, Joachim Szecsenyi & Freimut Schliess. (2020) Costs and its drivers for diabetes mellitus type 2 patients in France and Germany: a systematic review of economic studies. BMC Health Services Research 20:1.
Crossref
P. Uhl, C. Grundmann, M. Sauter, P. Storck, A. Tursch, S. Özbek, K. Leotta, R. Roth, D. Witzigmann, J.A. Kulkarni, V. Fidelj, C. Kleist, P.R. Cullis, G. Fricker & W. Mier. (2020) Coating of PLA-nanoparticles with cyclic, arginine-rich cell penetrating peptides enables oral delivery of liraglutide. Nanomedicine: Nanotechnology, Biology and Medicine 24, pages 102132.
Crossref
Tayla N. Rose, Michelle L. Jacobs, Debra J. Reid, Carla J. Bouwmeester, Michael P. Conley, Borna Fatehi, Thomas M. Matta & Judith T. Barr. (2020) Real-world impact on monthly glucose-lowering medication cost, HbA1c, weight, and polytherapy after initiating a GLP-1 receptor agonist. Journal of the American Pharmacists Association 60:1, pages 31-38.e1.
Crossref
John P Armato, Ralph A DeFronzo, Muhammad Abdul-Ghani & Ron J Ruby. (2018) Successful treatment of prediabetes in clinical practice using physiological assessment (STOP DIABETES). The Lancet Diabetes & Endocrinology 6:10, pages 781-789.
Crossref
Marco Orsini Federici, Janette McQuillan, Giovanni Biricolti, Serena Losi, Jeremie Lebrec, Catrina Richards, Cristiana Miglio & Kirsi Norrbacka. (2018) Utilization Patterns of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus in Italy: A Retrospective Cohort Study. Diabetes Therapy 9:2, pages 789-801.
Crossref
Victoria Divino, Mitch DeKoven, Farhad Ali Khan, Kristina S. Boye, Hélène Sapin & Kirsi Norrbacka. (2017) GLP-1 RA Treatment Patterns Among Type 2 Diabetes Patients in Five European Countries. Diabetes Therapy 8:1, pages 115-128.
Crossref
Xuesong Zhang, Sisi Liu, Yukun Li, Yan Wang, Meimei Tian & Guoqiang Liu. (2016) Long-Term Effectiveness and Cost-Effectiveness of Metformin Combined with Liraglutide or Exenatide for Type 2 Diabetes Mellitus Based on the CORE Diabetes Model Study. PLOS ONE 11:6, pages e0156393.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.